Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation

Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation.

We conducted a multicenter trial to evaluate the use of dronedarone in 4628 patients with atrial fibrillation who had additional risk factors for death. Patients were randomly assigned to receive dronedarone, 400 mg twice a day, or placebo. The primary outcome was the first hospitalization due to cardiovascular events or death. Secondary outcomes were death from any cause, death from cardiovascular causes, and hospitalization due to cardiovascular events.